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Abstract: Gold-coated silica nanoshells are a class of nanoparticles that can be designed to 
possess strong absorption of light in the near infrared (NIR) wavelength region. When injected 
intravenously, these nanoshells have been shown to accumulate in tumors and subsequently 
mediate photothermal treatment, leading to tumor regression. In this work, we sought to improve 
their speciﬁ  city by targeting them to prostate tumor cells. We report selective targeting of PC-3 
cells with nanoshells conjugated to ephrinA1, a ligand for EphA2 receptor that is overexpressed 
on PC-3 cells. We demonstrate selective photo-thermal destruction of these cells upon applica-
tion of the NIR laser.
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Introduction
Nanoshells are a class of nanoparticles consisting of an ultrathin metal shell sur-
rounding a dielectric core (Averitt et al 1999). Gold-coated silica nanoshells can be 
designed to possess strong absorption of light in the near infrared (NIR) wavelength 
region between 650–950 nm; this is signiﬁ  cant for biomedical applications as tissue 
components have minimal absorption at these wavelengths (Weissleder 2001). Gold 
nanoparticles are well suited for use in medicine due to the biocompatibility of gold; 
studies have shown no cytotoxicity of gold particles (Connor et al 2005). In addition, 
the gold surface allows easy conjugation of biomolecules to the surface by the use of 
a poly(ethylene glycol) (PEG) linker with a sulfur moiety (Loo et al 2005a; Lowery 
et al 2006). NIR-absorbing nanoshells have been used for cancer therapy (Hirsch et al 
2003; Lowery et al 2006), showing up to 100% regression of tumors after photothermal 
treatment (O’Neal et al 2004). These studies employed nontargeted nanoparticles that 
accumulated in the tumor tissues due to the enhanced permeability and retention (EPR) 
effect. It may be possible to achieve high efﬁ  cacy at lower nanoparticle dosages and 
also minimize nonspeciﬁ  c effects using targeted nanoparticles.
Eph receptors and ephrin ligands, a tyrosine kinase family of proteins, have 
been implicated in many types of cancers, including prostate, lung, esophageal, 
melanoma, leukemia colorectal, cervical, ovarian, and breast cancers (Surawska 
et al 2004; Brantley-Sieders et al 2004). Eph/Ephrin signaling plays an essential 
role in formation and maintenance of tissue organization by regulating cell adhesion, 
repulsion, and migration (Miao et al 2000; Marston et al 2003; Poliakov et al 2004). 
Abnormal Eph/Ephrin signaling activities and thus loss of cell-cell organization in 
tumors may be an important reason that tumors with high levels of expression of Eph 
receptor are more apt to metastasize and have poor prognosis (Fang et al 2005). In 
particular, a subclass of transmembrane Eph receptors, EphA2, has been shown to 
be overexpressed in prostate, melanoma, breast, and lung cancers (Walker-Daniels 
et al 1999; Zelinski et al 2001; Hess et al 2001; Brantley et al 2002; Kinch et al 2003; 
Ireton and Chen 2005).International Journal of Nanomedicine 2008:3(3) 352
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Metastatic prostate tumor cell lines, including LNCaPs 
and PC-3 cells, overexpress EphA2 by 10–100-fold 
as compared to noninvasive prostatic epithelial cells 
(Walker-Daniels et al 1999). Expression levels of EphA2 
are known to be progressively increased in more aggressive 
prostate cancer cell lines (Fox and Kandpal 2004; Fox et al 
2006). In addition, EphA2 immunoreactivity is signiﬁ  cantly 
greater in malignant human prostate carcinoma compared to 
benign prostate epithelium (Walker-Daniels et al 1999), and 
progressively higher levels of EphA2 were found in high-
grade prostatic cancers (Zeng et al 2003). Thus, it has been 
suggested that expression levels of EphA2 are correlated 
with disease stage, tumor metastasis, and poor prognosis 
(Ireton and Chen 2005). EphA2 receptor can be targeted 
by its natural ligand ephrinA1 or anti-EphA2 antibody. 
Once targeted by these moieties, EphA2 receptor becomes 
activated and starts signaling events that lead to inhibition 
and reversal of malignant phenotypes, such as proliferation, 
migration, and invasiveness (Carles-Kinch et al 2002; 
Zelinski et al 2001).
In this current study, we aimed to target and destroy pros-
tate cancer cells by targeting them with nanoshells conjugated 
to ephrinA1, a natural ligand for EphA2 receptor. We have 
conﬁ  rmed increased expression level of EphA2 receptor in a 
model prostate cancer cell line, PC-3. When NIR-absorbing 
nanoshells were conjugated with ephrinA1, they speciﬁ  cally 
bound to PC-3 cells, and subsequent photothermal therapy 
with NIR light selectively killed PC-3 cells, demonstrating 
the efﬁ  cacy of targeted nanoshell therapy.
Methods and materials
All chemicals were purchased from Sigma-Aldrich (St. Louis, 
MO, USA) unless otherwise noted.
Nanoshell synthesis
Gold nanoshell synthesis has been previously described by 
others (Oldenburg et al 1998). Brieﬂ  y, nanoshells were made 
through a four-step procedure. First, silica cores were grown 
using the Stöber process, the basic reduction of tetraethyl 
orthosilicate (TEOS). 45 ml of 200-proof ethanol was used 
with 3.0–4.0 ml of 14.8 N NH4OH to make six batches at 
different ammonia volumes. 1.5 ml TEOS was added to 
each batch and allowed to react a minimum of 8 hr. Silica 
precipitates were centrifuged and washed with 200-proof 
ethanol twice to remove any remaining NH4OH. The resul-
tant silica nanoparticles were sized using scanning electron 
microscopy (SEM; Philips FEI XL30). Average diameters 
of different batches ranged between 98–112 nm. Only 
batches with a polydispersity of less than 10% were used in 
subsequent steps. Reaction of the silica core nanoparticles 
with 200 μl of (3-aminopropyl) triethoxysilane (APTES) per 
batch provided amine groups on the surface of the cores to 
allow for adsorption of gold colloid in the subsequent step. 
Aminated silica cores were boiled for 2 hr with addition 
of 200-proof ethanol to maintain volume, then cooled and 
washed twice by centrifugation. The silica core suspensions 
were measured to determine the weight percent of solids and 
adjusted to 4 wt% for storage by addition of ethanol. Next, 
gold colloid was prepared to a size of 2–4 nm as by the 
method of Duff and colleagues (1993) and aged 2–3 weeks at 
4 °C. The colloid was then concentrated ∼20× through rotary 
evaporation and mixed with the aminated silica particles at 
a volume of 10 ml concentrated colloid:300 μl stored silica 
core suspension; thus allowing small gold colloid to attach 
to the larger silica nanoparticle surface to act as nucleation 
sites in the subsequent reduction step. This resulted in 
the seed particles form which nanoshells are grown. Seed 
particle suspensions were adjusted to have an absorbance 
at 530 nm = 0.1.
Finally, the gold shell was then grown by reduction of 
gold using 0.4 mM HAuCl4 solution (plating solution) in 
the presence of formaldehyde. To produce particles with 
varying shell thicknesses, we varied the concentration of 
seed particles while using the same amount of plating solu-
tion. NIR absorption characteristics of the nanoshells were 
determined using a UV-Vis spectrophotometer (Carey 5000 
Varian, Walnut Creek, CA). Samples with the appropriate 
NIR peak resonance (∼800 nm) were scaled up linearly to 
provide nanoshells for the experiment.
EphrinA1 conjugation to nanoshells
A bi-functional PEG derivative, orthopyridyl-disulﬁ  de-
poly(ethylene glycol)-N-hydroxysuccinimide ester 
(OPSS-PEG-NHS, 2000MW) was obtained from Nektar 
(Birmingham, AL, USA). The NHS group is cleaved in 
water, leaving an activated carboxylic group, which reacts 
with a primary amine in biomolecules to form amide bond 
between the PEG chain and biomolecules of interest. 
A disulﬁ  de group in the OPSS end allows self-assembly 
of the biomolecules conjugated to the PEG chains on the 
gold surface of nanoshells. Recombinant fusion proteins of 
mouse ephrinA1/Fc chimera (R and D Systems, Minneapolis, 
MN, USA) were reacted with bi-functional PEG at a mole 
ratio of 20:1. Reactants were dissolved in 100 mM sodium 
bicarbonate at pH 8.5. The final concentration of the 
OPSS-PEG-ephrinA1 conjugate was approximately 8.25 μM, International Journal of Nanomedicine 2008:3(3) 353
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and the product was used to bind to the gold surface of the 
nanoshell. OPSS-PEG-ephrinA1 was incubated at a ratio of 
1500 molecules per nanoshell for 4 hr to allow self-assembly 
of the disulﬁ  de end of the molecule to the gold surface. 
Nanoshells were then further coated with PEG to block any 
remaining uncovered gold surfaces. This was accomplished 
by adding 20 μl of 5 μM of PEG-thiol (Nektar, Huntsville, 
AL, USA) to 1.5 × 1010 nanoshells/ml in DI water. Control 
PEG-nanoshells were synthesized in parallel by binding 
PEG-thiol to the gold surface of the nanoshells. Conjugated 
nanoshells were sterilized by ﬁ  ltration using a 0.22 μm ﬁ  lter. 
Extinction spectra of ephrinA1-, PEG- and bare nanoshells 
were obtained from 400 nm to 1100 nm with Carey UV-Vis 
spectrophotometer.
Cell culture
Human prostate cancer cells, PC-3 cells, obtained from ATCC, 
were grown in Ham’s F12K media (ATCC, Manassas, VA, 
USA) supplemented with 4 mM l-glutamine, 1% penicillin, 
1% streptomycin and 10% fetal bovine serum (FBS). Cells 
were detached from culture with trypsin (0.05%) and EDTA 
(0.02%) and re-suspended in media for passaging to wells. 
As controls, human dermal ﬁ  broblasts (HDFs) were grown 
in DMEM supplemented with 4 mM l-glutamine, 1% peni-
cillin, 1% streptomycin and 10% FBS. Cells were detached 
from culture with trypsin (0.05%) and EDTA (0.02%) and 
re-suspended in media for passaging to wells.
Immunoﬂ  uorescence staining
PC-3 and HDF cells were seeded on cover-slips pre-adsorbed 
with ﬁ  bronectin (10 μg/ml) for 2 hr. After the cells were 
cultured to form a conﬂ  uent monolayer, they were ﬁ  xed with 
4% formaldehyde for 15 min and then permeabilized with 
0.5% triton X-100 for 5 min. After incubating the samples 
with a 3% bovine serum albumin (BSA) in PBS for 2 hr, the 
samples were incubated with anti-EphA2 mouse antibody 
(Upstate, Lake Placid, NY, USA) at a concentration of 
10 μg/ml in 1% BSA solution for 2 hr. The samples were 
then incubated with anti-mouse IgG conjugated with Alexa 
ﬂ  uor 488 (Invitrogen, Carlsbad, CA, USA) at concentration of 
10 μg/ml in 1% BSA solution for 2 hr. Cell nuclei were stained 
with 300 nM DAPI (Invitrogen) for 10 min. Controls without 
primary antibody were prepared in parallel. The samples were 
imaged with a confocal microscope (Zeiss Live 5).
Cellular targeting of nanoshells
PC-3 and HDF cells were seeded on cover-slips pre-adsorbed 
with ﬁ  bronectin (10 μg/ml) for 2 hr. After 3 days in culture, 
the cells were incubated with nanoshells; ephrinA1-, PEG-, 
and bare nanoshells were suspended in media appropriate 
for the cell lines to a concentration of 3 × 109 nanoshells/ml. 
Cells were incubated with the suspensions for 2 hr and 
rinsed twice with PBS. After mounting cover-slips, the 
samples were visualized with Axiovert 135 phase contrast 
microscope (Carl Zeiss, Thornwood, NJ, USA), equipped 
with a darkﬁ  eld attachment from CytoViva (Auburn, AL, 
USA). Images were taken with Nikon D80 Digital SLR. 
For visualization of the cells and nanoshells with confocal 
microscopy, the cells were stained with Cell Tracker Orange 
CMTMR (Invitrogen) at 2.5 μM for 1 hr prior to incubation 
with nanoshells. The cells were visualized with confocal 
microscope in ﬂ  uorescence mode and the nanoshells in 
reﬂ  ectance mode.
Photothermal ablation of cells
PC-3 and HDF cells were grown in tissue culture plastic 
wells and incubated with either ephrinA1-, PEG-, or bare 
nanoshells. Nanoshells were suspended in media appropriate 
for the cell line at a concentration of 3 × 109 nanoshell/ml. 
Cells were incubated with nanoshell suspensions for 2 hr 
and rinsed twice with PBS. Laser ablation was accomplished 
using an Integrated Fiber Array Packet, FAP-I System, with 
a wavelength of 808 nm (Coherent, Santa Clara, CA, USA) 
at a power density of 80 W/cm2 and a spot size of ∼2 mm 
diameter for 7 min.
After irradiation, cells were rinsed gently with PBS and 
incubated with appropriate media. After incubation for 4 hrs, 
cell viability was assessed using a Live/Dead stain kit from 
Molecular Probes (Invitrogen). Dilutions recommended by 
the manufacturer were followed for the staining procedure 
using PBS. 2.5 μl of calcein AM and 8.0 μl of ethidium 
homodimer-1 were used per 10 ml of PBS. Cells were incu-
bated for 45 min prior to imaging. In this stain, the calcein 
AM enters the cells and is cleaved by esterases in live cells 
to yield cytoplasmic green ﬂ  uorescence. Dead cells, hav-
ing compromised nuclear membranes, allow the ethidium 
homodimer-1 to enter and bind nucleic acids generating a 
red ﬂ  uorescence.
Results
Expression of EphA2 on PC-3 cells
EphA2 are known to be overexpressed in prostate, mela-
noma, breast, and lung cancers (Walker-Daniels et al 1999; 
Zelinski et al 2001; Hess et al 2001; Brantley et al 2002; 
Kinch et al 2003; Ireton and Chen 2005). In order to conﬁ  rm 
high expression levels of EphA2 in prostate cell lines, we International Journal of Nanomedicine 2008:3(3) 354
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performed immunoﬂ  uorescence staining of EphA2 on PC-3 
cells. As shown in Figure 1A and 1C, PC-3 cells incubated 
with antibody against the EphA2 receptor showed strong 
ﬂ  uorescence (green) whereas HDF had minimal ﬂ  uorescence 
signal. There was minimal background signal as shown with 
PC-3 cells and HDF incubated only with the secondary anti-
body conjugated with ﬂ  uorophores (Figure 1B and 1D).
Nanoshell spectra after EphrinA1 
conjugation
Nanoshells were designed to have peak absorption in 
the near infrared. Nanoshells were made to be 142 nm in 
diameter with a 12 nm thick shell and had peak absorption 
at 800 nm. There was minimal spectral shift of only ∼5.0 nm 
of the peak at 780 nm after ephrinA1 or PEG conjugation to 
nanoshells (Figure 2). This demonstrates negligible effect 
of biomolecule conjugation on the optical properties of the 
nanoshells.
Binding of EphrinA1-nanoshells 
to PC-3 cells
Nanoshells are known to both absorb and scatter light 
at its maximal extinction wavelength (Loo et al 2005a). 
In order to visualize nanoshells bound to cells, confocal 
HDF
anti-mouse IgG-FITC anti-EphA2
PC-3
A)
C) C)
B) B)
D)
50 μm
Figure 1 Immunoﬂ  uorescence staining of human prostate cancer cells.  A) A model prostate cancer cell line, PC-3, stained with anti-EphA2 antibody, shows abundant expression 
level of EphA2 receptor C) whereas there is no detectable level in HDF cells. B), D) PC-3 and HDF cells incubated with only secondary antibody conjugated with Alex ﬂ  uor 
488 had minimal ﬂ  uorescence background. DAPI is shown in blue.International Journal of Nanomedicine 2008:3(3) 355
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microscopy was used on PC-3 cells and HDF incubated with 
ephrinA1-nanoshells for 2 hrs. Images of nanoshells obtained 
in reﬂ  ectance mode at 633 nm and cells pre-labeled with 
Cell Tracker Orange CMTMR were overlaid and shown in 
Figure 3. EphrinA1-nanoshells bound speciﬁ  cally to PC-3 
cells. EphrinA1-nanoshells decorated majority of PC-3 cells 
whereas there was no binding of ephrinA1-nanoshells on 
HDF. PEG-nanoshells without the ligand for EphA2 did not 
bind to either cell types. On the other hand, bare nanoshells 
bound to both cell types as well as on ﬁ  bronectin-coated glass 
substrates due to protein adsorption to the gold surface.
Darkﬁ  eld microscopy was also used to visualize the 
nanoshells. Figure 4A shows ephrinA1-nanoshells bound to 
PC-3 cells as bright spots against the darker background of 
cell bodies and substrates. Images in higher magniﬁ  cation 
provide better details of the bound nanoshells (Figure 4B). 
There was good coverage of ephrinA1-nanoshells over the 
entire surface of PC-3 cells. PEG-nanoshells did not bind to 
PC-3 cells (Figure 4C) whereas bare nanoshells bound to both 
the cells and substrates nonspeciﬁ  cally (Figure 4D). HDF had 
minimal number of ephrinA1-nanoshells (Figure 4E).
Targeted photothermal ablation
EphrinA1-nanoshells bound speciﬁ  cally to PC-3 cells, thus 
allowing targeted destruction of prostate tumor cell lines with 
NIR light-induced photothermal ablation. As described in the 
methods and materials, the NIR light at 808 nm was applied 
to cells incubated with the nanoshells. Figure 5 shows cells 
stained with live/dead stain after treatment with the NIR 
laser. PC-3 cells targeted with ephrinA1-nanoshells had a 
zone of dead cells, corresponding to the circular pattern of 
the NIR laser spot (Figure 5A). However, control HDF that 
underwent the same treatment with ephrinA1-nanoshells 
and NIR laser ablation did not show any sign of cell death 
(Figure 5B). As expected, both cell types were viable after 
exposure to PEG-nanoshells and laser treatment whereas 
similar treatment with bare nanoshells resulted in cell death 
in both cell types.
Discussion
The work presented here shows that PC-3 cell line can be 
speciﬁ  cally targeted and destroyed by nanoshells conjugated 
to ephrinA1. We ﬁ  rst conﬁ  rmed previous reports of increased 
expression level of EphA2 receptor in prostate cancer cell 
lines by immunoﬂ  uorescence staining. High levels of the 
EphA2 receptor in PC-3 cells allowed selective binding and 
accumulation of ephrinA1 conjugated nanoshells over a 
control cell line, HDF, which had minimal level of EphA2 
expression. Using both reﬂ  ectance confocal microscopy 
and darkﬁ  eld microscopy, we have visualized ephrinA1-
nanoshells decorating surface of PC-3 cells. Finally, PC-3 
cells incubated with ephrinA1-nanoshells were destroyed 
with NIR laser matched to the peak resonance of the 
nanoshells.
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Figure 2 Spectra of nanoshells before and after surface conjugation of ephrinA1 or PEG.   There is minimal shift in the peak after conjugation, indicating that the nanoshells 
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Nanoshell therapy possesses several advantages over 
chemotherapy or radiation therapy. First, the use of the gold-
coated nanoshells does not present a danger to the patient 
in terms of toxicity and overall side effects. Secondly, the 
nanoparticles can passively accumulate to the tumor based on 
the intrinsic biology of the tumor. Third, the use of targeted 
nanoshells should increase localized accumulation and allow 
speciﬁ  c targeting of malignant cells over the normal tissues. 
Finally, the nanoshells will only heat up and destroy tumors in 
the presence of NIR light activation, thus localizing treatment 
to the exact site needed.
The therapeutic beneﬁ  ts of nanoshells are realized after the 
particles are heated by absorption of NIR laser energy. Neither 
the nanoshells nor the NIR laser by themselves produce any 
damaging effects to the tissue; it is the combination of the two 
within the tumors that produce hyperthermia and thus ablation 
of the tumor. Solid gold nanoparticles do not induce cytotox-
icity (Connor et al 2005), whereas chemotherapeutic agents 
produce systemic side effects while treating certain tumors.
Energy absorption by tissues in NIR window is minimal 
(Weissleder 2001). Thus, NIR laser irradiation permits 
deep penetration of the laser energy into tumor, and heat 
generated from nanoshells irradiated with NIR raises the 
local temperature, causing irreversible thermal damage. Two 
innocuous components, nanoshells and NIR laser irradiation, 
can be combined to produce an effective therapy, minimizing 
harmful effects to the patient. The ability of the nanoshell 
to both absorb and scatter energy based on its design has 
permitted imaging of tumors using optical methods (Gobin 
et al 2007), and targeted nanoshells hold the potential for 
simultaneous imaging and treatment of cancers (Loo et al 
2005b). In the treatment of aggressive prostate cancer, 
these types of options will provide an improved therapeutic 
since targeted nanoshells will allow surgeons to locate the 
malignant cells and destroy them locally and speciﬁ  cally.
This study used a prostate cancer cell line as a tumor 
model to demonstrate the efﬁ  cacy of using ephrinA1 as a 
targeting moiety in nanoshell therapy. Promising results 
from this study suggests that EphA2 receptor may serve 
as a targeting moiety in other types of tumor such as mela-
noma, breast and lung cancers with high expression levels 
of EphA2 (Walker-Daniels et al 1999; Zelinski et al 2001; 
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Figure 3 Reﬂ  ective confocal images of nanoshells bound to cells. PC-3 cells pre-labeled with Cell Tracker Orange were incubated with A) ephrinA1-, B) PEG-, and C) bare 
nanoshells and visualized with confocal microscopy. Surface-bound nanoshells are shown in green. A large number of ephrinA1- nanoshells and bare nanoshells bound to PC-3 
cells. On the other hand, D), E), F) only bare nanoshells associated with the control HDF cells.International Journal of Nanomedicine 2008:3(3) 357
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Figure 4 Darkﬁ  eld images of nanoshells bound to cells.  A) EphrinA1-nanoshells bound to the PC-3 cells with high expression of EphA2 receptor. B) shows higher magniﬁ  cation 
of A). C) PEG-nanoshells had minimal binding whereas D) bare nanoshells bound indiscriminately to PC-3 cells and the substrate. E) EphrinA1-nanoshells had minimal binding 
to HDF. Scale bars in A), C) and E) = 50 μm and B) and D) = 10 μm.
A) B)
C) B) D)
E)
Figure 5 Live/dead stain of cells incubated with nanoshells and exposed to the NIR laser with a spot size of 2 mm. PC-3 cells were incubated with A) ephrinA1-, B) PEG-, 
and C) bare nanoshells for 2 hrs and then exposed to the NIR laser in the center of the wells, and D), E), and F) HDF underwent the same treatment. Note that the bare 
nanoshells allowed ablation of both cell types indiscriminately while ephrinA1-nanoshells allowed ablation of only PC-3 cell line. Live and dead cells are shown in green and 
red, respectively.
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Hess et al 2001; Brantley et al 2002; Kinch et al 2003; Ireton 
and Chen 2005). In addition, a large percentage of cells within 
these tumors are known to overexpress EphA2 receptor, and 
the most aggressive tumor cells show the highest levels of 
EphA2 (Fox and Kandpal 2004; Fox et al 2006). Therefore, 
nanoshells targeting EphA2 via ephrinA1 ligand may be 
an excellent candidate for targeting and destroying a wide 
variety of tumors.
This work demonstrated that we can achieve good con-
jugation of biomolecules speciﬁ  cally targeted for prostate 
cancer cells on nanoshells without signiﬁ  cant changes in their 
spectral properties. EphA2 receptor protein overexpressed on 
surface of prostate cancer cells were targeted by its compli-
mentary ligand, ephrinA1, conjugated onto nanoshells. PC-3 
cells bound with these nanoshells were destroyed when laser 
energy benign to normal tissue was applied. It is expected 
that this targeting scheme should enhance the uptake of 
nanoshells to tumors and thus increase the efﬁ  cacy of the 
nanoshell therapy in vivo.
Disclosure
Andre M Gobin and James J Moon contributed equally to this 
work. This work was funded by NIH and NSF. The authors 
report no conﬂ  icts of interest.
References
Averitt RD, Westcott SL, Halas NJ. 1999. Linear optical properties of gold 
nanoshells. J Optic Soc Am B, 16:1824–32.
Brantley-Sieders D, Schmidt S, Parker M, et al. 2004. Eph receptor tyrosine 
kinases in tumor and tumor microenvironment. Curr Pharm Des, 
10:3431–42.
Brantley DM, Cheng N, Thompson EJ, et al. 2002. Soluble Eph A receptors 
inhibit tumor angiogenesis and progression in vivo. Oncogene, 
21:7011–26.
Carles-Kinch K, Kilpatrick KE, Stewart JC, et al. 2002. Antibody targeting 
of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer 
Res, 62:2840–7.
Connor EE, Mwamuka J, Gole A, et al. 2005. Gold nanoparticles are taken up 
by human cells but do not cause acute cytotoxicity. Small, 1:325–7.
Duff DG, Baiker A, Edwards PP. 1993. A new hydrosol of gold clusters. 
1. Formation and particle size variation. Langmuir, 9:2301–9.
Fang WB, Brantley-Sieders DM, Parker MA, et al. 2005. A kinase-
dependent role for EphA2 receptor in promoting tumor growth and 
metastasis. Oncogene, 24:7859–68.
Fox BP, Kandpal RP. 2004. Invasiveness of breast carcinoma cells and 
transcript proﬁ  le: Eph receptors and ephrin ligands as molecular markers 
of potential diagnostic and prognostic application. Biochem Biophys 
Res Commun, 318:882–92.
Fox BP, Tabone CJ, Kandpal RP. 2006. Potential clinical relevance of Eph 
receptors and ephrin ligands expressed in prostate carcinoma cell lines. 
Biochem Biophys Res Commun, 342:1263–72.
Gobin AM, Lee MH, Halas NJ, et al. 2007. Near-infrared resonant nanoshells 
for combined optical imaging and photothermal cancer therapy. Nano 
Lett, 7:1929–34.
Hess AR, Seftor EA, Gardner LM, et al. 2001. Molecular regulation of 
tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of 
epithelial cell kinase (Eck/EphA2). Cancer Res, 61:3250–5.
Hirsch LR, Jackson JB, Lee A, et al. 2003. A whole blood immunoassay 
using gold nanoshells. Anal Chem, 75:2377–81.
Ireton RC, Chen J. 2005. EphA2 receptor tyrosine kinase as a promising 
target for cancer therapeutics. Curr Cancer Drug Targets, 5:149–57.
Kinch MS, Moore MB, Harpole DH, Jr. 2003. Predictive value of the EphA2 
receptor tyrosine kinase in lung cancer recurrence and survival. Clin 
Cancer Res, 9:613–18.
Loo C, Hirsch L, Lee M-H, et al. 2005a. Gold nanoshell bioconjugates for 
molecular imaging in living cells. Opt Lett, 30:1012–14.
Loo C, Lowery A, Halas N, et al. 2005b. Immunotargeted nanoshells for 
integrated cancer imaging and therapy. Nano Lett, 5:709–11.
Lowery AR, Gobin AM, Day ES, et al. 2006. Immunonanoshells for targeted 
photothermal ablation of tumor cells. Int J Nanomed, 1:149–54.
Marston DJ, Dickinson S, Nobes CD. 2003. Rac-dependent trans-
endocytosis of ephrinBs regulates Eph-ephrin contact repulsion. Nat 
Cell Biol, 5:879–88.
Miao H, Burnett E, Kinch M, et al. 2000. Activation of EphA2 kinase 
suppresses integrin function and causes focal-adhesion-kinase dephos-
phorylation. Nat Cell Biol, 2:62–9.
O’Neal DP, Hirsch LR, Halas NJ, et al. 2004. Photo-thermal tumor abla-
tion in mice using near infrared-absorbing nanoparticles. Cancer Lett, 
209:171–6.
Oldenburg SJ, Averitt RD, Westcott SL, et al. 1998. Nanoengineering of 
optical resonances. Ch Phys Lett, 288:243–7.
Poliakov A, Cotrina M, Wilkinson DG. 2004. Diverse roles of eph receptors 
and ephrins in the regulation of cell migration and tissue assembly. 
Dev Cell, 7:465–80.
Surawska H, Ma PC, Salgia R. 2004. The role of ephrins and Eph receptors 
in cancer. Cytokine Growth Factor Rev, 15:419–33.
Walker-Daniels J, Coffman K, Azimi M, et al. 1999. Overexpression of the 
EphA2 tyrosine kinase in prostate cancer. Prostate, 41:275–80.
Weissleder R. 2001. A clearer vision for in vivo imaging. Nat Biotechnol, 
19:316–7.
Zelinski DP, Zantek ND, Stewart JC, et al. 2001. EphA2 overexpression 
causes tumorigenesis of mammary epithelial cells. Cancer Res, 
61:2301–6.
Zeng G, Hu Z, Kinch MS, et al. 2003. High-level expression of EphA2 
receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J 
Pathol, 163:2271–6.